Cargando…
非小细胞肺癌免疫治疗生物标志物研究进展
Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent o...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796128/ https://www.ncbi.nlm.nih.gov/pubmed/35078285 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.55 |
Ejemplares similares
-
非小细胞肺癌免疫治疗生物标志物的研究进展
Publicado: (2021) -
非小细胞肺癌新辅助免疫治疗生物标志物研究进展
Publicado: (2022) -
非小细胞肺癌免疫检查点抑制剂治疗相关外周血生物标志物研究进展
Publicado: (2021) -
小细胞肺癌免疫治疗及预后相关标志物的研究进展
Publicado: (2020) -
非小细胞肺癌免疫治疗进展
Publicado: (2014)